<DOC>
	<DOC>NCT02815839</DOC>
	<brief_summary>The objective of the study is to assess the safety, tolerance, food effect, pharmacokinetic and pharmacodynamic properties of single dose adminstration of SHR4640 in healthy volunteers.</brief_summary>
	<brief_title>Single Dose Study of SHR4640 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<criteria>Body weight≥50, BMI:1924kg/m2; Screening serum urate level ≤ 4.5 mg/dL for male and ≤ 3.5 mg/dL for female; Medically stable based on physical examination, medical history, laboratory results, vital sign measurements, and 12lead electrocardiogram (ECG) at screening; History of hyperuricemia or gout. Pregnancy or breastfeeding; History or suspicion of kidney stones; serum creatinine＞1.5mg/dl for male, ＞1.2mg/dl for female; alanine aminotransferase and/or aspartate aminotransferase＞2 upper limit of normal, or total bilirubin＞2.5 upper limit of normal.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>urate transporter 1</keyword>
	<keyword>SHR4640</keyword>
	<keyword>single ascending dose</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>